natgillin/translations-raw huggingface dataset:
One hard capsule contains cabozantinib (S)-malate equivalent to 20 mg or 80 mg cabozantinib. 
Ena trda kapsula vsebuje kabozantinib (S)-malat v količini, ki ustreza 20 mg ali 80 mg kabozantiniba.
Each daily dose is provided in one row and contains one 80 mg capsule and three 20 mg capsules: 
Vsak dnevni odmerek je v eni vrsti in vsebuje eno 80 mg kapsulo in tri 20 mg kapsule:
one orange 80 mg + three grey 20 mg 
= 100 mg ena oranžna 80 mg + tri sive 20 mg
21 x 20 mg capsules and 7 x 80 mg capsules (140 mg/day dose for a 7-day supply) Each 140 mg daily dose contains a combination of three grey 20 mg capsules and one orange 80 mg capsule. 
Pakiranje s 140 mg dnevnim odmerkom21 x 20 mg in 7 x 80 mg kapsule (odmerek 140 mg/dan, zaloga za 7 dni) En 140 mg dnevni odmerek vsebuje kombinacijo treh sivih 20 mg kapsul in ene oranžne 80 mg kapsule.
The COMETRIQ 20 mg capsules contain cabozantinib (S)-malate equivalent to 20 mg of cabozantinib. 
Zdravilo COMETRIQ 20 mg kapsule vsebuje kabozantinib (S)-malat v količini, ki ustreza 20 mg kabozantiniba.
Hypertension has been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili hipertenzijo.
• Wounds that have difficulties healing 
• rane, ki se slabo celijo
The 100 mg daily dose blister card contains seven 80 mg capsules and seven 20 mg capsules as 7 daily doses in total. 
Pretisna zgibanka s 100 mg dnevnim odmerkom vsebuje sedem 80 mg kapsul in sedem 20 mg kapsul, kar je skupaj 7 dnevnih odmerkov.
COMETRIQ 20 mg COMETRIQ 80 mg 140 mg/day dose 
COMETRIQ 20 mg COMETRIQ 80 mg odmerek 140 mg/dan
COMETRIQ 20 mg COMETRIQ 80 mg 100 mg/day dose 
COMETRIQ 20 mg COMETRIQ 80 mg odmerek 100 mg/dan
BLISTER CARD, 60 mg dose 
PRETISNA ZGIBANKA, odmerek 60 mg
84 capsules (4 blister cards of 21 x 20 mg) (60 mg/day dose) 56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose) 112 capsules (4 blister cards of 21 x 20 mg and 7 x 80 mg) (140 mg/day dose) 
84 kapsul (4 pretisne zgibanke z: 21 x 20 mg) (odmerek 60 mg/dan) 56 kapsul (4 pretisne zgibanke z: 7 x 20 mg in 7 x 80 mg) (odmerek 100 mg/dan) 112 kapsul (4 pretisne zgibanke z: 21 x 20 mg in 7 x 80 mg) (odmerek 140 mg/dan)
COMETRIQ 20 mg hard capsules 
COMETRIQ 20 mg trde kapsule
COMETRIQ 20 mg hard capsules Cabozantinib 
COMETRIQ 20 mg trde kapsule kabozantinib
EU/1/13/890/006 112 capsules (4 blister cards of 21 x 20mg and 7 x 80 mg) (140 mg/day dose for 28 
EU/1/13/890/006 112 kapsul (4 pretisne zgibanke z: 21 x 20 mg in 7 x 80 mg) (odmerek
A high-fat meal moderately increased Cmax and AUC values (41% and 57%, respectively) relative to fasted conditions in healthy volunteers administered a single 140 mg oral cabozantinib dose. 
Obrok z visoko vsebnostjo maščob je pri zdravih prostovoljcih, ki so dobili en peroralni odmerek 140 mg kabozantiniba zmerno zvišal vrednosti Cmax in AUC (41 % oz. 57 %) v primerjavi s stanjem na tešče.
56 capsules (4 blister cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose for a 28 day supply) 112 capsules (4 blister cards of 21 x 20mg and 7 x 80 mg) (140 mg/day dose for a 28 day supply) 
56 kapsul (4 pretisne zgibanke s: 7 x 20 mg in 7 x 80 mg) (odmerek 100 mg/dan, zaloga za 28 dni) 112 kapsul (4 pretisne zgibanke z: 21 x 20 mg in 7 x 80 mg) (odmerek 140 mg/dan odmerek, zaloga za 28 dni)
BLISTER CARD OF 28 DAY PACK, 60 mg dose (WITHOUT BLUE BOX) 
PRETISNA ZGIBANKA 28-DNEVNO PAKIRANJE, odmerek 60 mg (BREZ BLUE-BOXA)
The 140 mg daily dose blister card contains seven 80 mg capsules and twenty one 20 mg capsules as 7 doses in total. 
Pretisna zgibanka s 140 mg dnevnim odmerkom vsebuje sedem 80 mg kapsul in enaindvajset 20 mg kapsul, kar je skupaj 7 dnevnih odmerkov.
7 x 20 mg capsules and 7 x 80 mg capsules (100 mg/day dose for a 7-day supply). 
7 x 20 mg in 7 x 80 mg kapsule (odmerek 100 mg/dan, zaloga za 7 dni).
21 x 20 mg capsules and 7 x 80 mg capsules (140 mg/day dose for a 7-day supply). 
21 x 20 mg in 7 x 80 mg kapsule (odmerek 140 mg/dan, zaloga za 7 dni).
Figure 1: Kaplan Meier curve of progression free survival 
Slika 1: Krivulja preživetja brez napredovanja bolezni po lestvici Kaplan-Meier
Hemorrhage has been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili krvavitve.
Cabozantinib should be discontinued in patients who develop nephrotic syndrome. 
Pri bolnikih, pri katerih se razvije nefrotični sindrom, je treba z uporabo kabozantiniba prenehati.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/890/002 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/890/002
• A condition called posterior reversible encephalopathy syndrome (PRES) or reversible posterior leukoencephalopathy syndrome (RPLS), which has symptoms such as seizures, headaches, 
Posterior Leukoencephalopathy Syndrome), znan tudi kot sindrom posteriorne reverzibilne encefalopatije (PRES, Posterior Reversible Encephalopathy Syndrome) s simptomi, kot so epileptični napadi, glavobol, zmedenost ali težave s koncentracijo
MARKETING AUTHORISATION NUMBER(S) EU/1/13/890/001 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/890/001
You should also tell your dentist that you are taking COMETRIQ. 
Če jemljete zdravilo COMETRIQ, to povejte svojemu zobozdravniku.
The 60 mg daily dose blister card contains twenty-one 20 mg capsules as 7 daily doses in total. 
Pretisna zgibanka s 60 mg dnevnim odmerkom vsebuje enaindvajset 20 mg kapsul, kar je skupaj 7 dnevnih odmerkov.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/890/005 56 capsules (4 blisters cards of 7 x 20 mg and 7 x 80 mg) (100 mg/day dose for 28 day supply) 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/890/005 56 kapsul (4 pretisne zgibanke po 7 x 20 mg in 7 x 80 mg) (odmerek
21 x 20 mg capsules (60 mg/day dose for a 7-day supply). 
21 x 20 mg kapsul (odmerek 60 mg/dan, zaloga za 7 dni).
7 x 20 mg and 7 x 80 mg capsules (100 mg/day dose for a 7-day supply) 21 x 20 mg and 7 x 80 mg capsules (140 mg/day dose for a 7-day supply) 
7 x 20 mg in 7 x 80 mg kapsule (odmerek 100 mg/dan, zaloga za 7 dni) 21 x 20 mg in 7 x 80 mg kapsule (odmerek 140 mg/dan, zaloga za 7 dni) 28-dnevno pakiranje, ki vsebuje:
MARKETING AUTHORISATION NUMBER(S) EU/1/13/890/003 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/890/003
Proteinuria has been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili proteinurijo.
These may be signs of a condition called reversible posterior leukoencephalopathy syndrome (RPLS). 
• Stanje, imenovano sindrom posteriorne reverzibilne levkoencefalopatije (RPLS, Reversible
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON OF 28 DAY PACK, 140 mg dose (INCLUDING BLUE BOX) 
ZUNANJA OVOJNINA ENOTE PAKIRANJA ZA 28 DNI, odmerek 140 mg (VKLJUČNO Z BLUE BOXOM)
14.6 months 
14,6 mesecev n/v
• Tear or hole or bleeding in your stomach or intestine, inflammation or tear of anus, , bleeding in lungs or trachea (airway) 
• raztrganje, luknja ali krvavitev v želodcu ali prebavilih, vnetje ali raztrganje zadnjika,
General disorders and administration site conditions fatigue, mucosal inflammation, asthenia impaired wound healing, chills, face oedema cyst, facial pain, localised oedema 
Splošne težave in spremembe na mestu aplikacije utrujenost, vnetje sluznice, astenija slabše celjenje ran, mrzlica, obrazni edem cista, bolečine obraza, lokaliziran edem
How to store COMETRIQ 
Shranjevanje zdravila COMETRIQ
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON OF 28 DAY PACK, 100 mg dose (INCLUDING BLUE BOX) 
ZUNANJA OVOJNINA ENOTE PAKIRANJA ZA 28 DNI, odmerek 100 mg (VKLJUČNO Z BLUE BOXOM)
Hepatobiliary disorders cholelithiasis 
Bolezni jeter, žolčnika in žolčevodov holelitiaza
There is little experience with cabozantinib in non-White patients. 
Rasa Pri nebelcih je le malo izkušenj s kabozantinibom.
MARKETING AUTHORISATION NUMBER(S) EU/1/13/890/004 84 capsules (4 blisters cards of 21 x 20 mg) (60 mg/day dose for 28 day supply) 13. 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/890/004 84 kapsul (4 pretisne zgibanke po 21 x 20 mg) (odmerek 60 mg/dan, zaloga za
MARKETING AUTHORISATION NUMBER(S) EU/1/13/890/006 112 capsules (4 blisters cards of 21 x 20 mg and 7 x 80 mg) (140 mg/day dose for 28 day supply) 
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/13/890/006 112 kapsul (4 pretisne zgibanje z 21 x 20 mg in 7 x 80 mg) (odmerek
PARTICULARS TO APPEAR ON THE OUTER PACKAGING OUTER CARTON OF 28 DAY PACK, 60 mg dose (INCLUDING BLUE BOX) 
ZUNANJA OVOJNINA ENOTE PAKIRANJA ZA 28 DNI, odmerek 60 mg (VKLJUČNO Z BLUE BOXOM)
Cabozantinib should be used with caution in patients with mild or moderate renal impairment. 
Pri bolnikih z blago ali zmerno ledvično okvaro je treba kabozantinib uporabljati previdno.
PHARMACEUTICAL FORM AND CONTENTS 100 mg Dose 28 day pack: 56 capsules (4 blister cards of 7 x 20 mg capsules and 7 x 80 mg capsules) for the 100 mg daily dose for a 28 day supply. 
28-dnevno pakiranje: 56 kapsul (4 pretisne zgibanke s: 7 x 20 mg kapsulami in 7 x 80 mg kapsulami) za odmerek 100 mg na dan, zaloga za 28 dni.
Tel: +372 60 15 540 Ελλάδα, Κύπρος, Malta 
Tel: +372 60 15 540
PHARMACEUTICAL FORM AND CONTENTS 140 mg Dose 28 day pack: 112 capsules (4 blister cards of 21 x 20 mg capsules and 7 x 80 mg capsules) for the 140 mg daily dose for a 28 day supply. 
28-dnevno pakiranje: 112 kapsul (4 pretisne zgibanke z: 21 x 20 mg kapsulami in 7 x 80 mg kapsulami) za odmerek 140 mg na dan, zaloga za 28 dni.
• Swollen lymph glands 
• otekle bezgavke
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BLISTER CARD OF 28 DAY PACK, 140 mg dose (WITHOUT BLUE BOX) 
PRETISNA ZGIBANKA 28-DNEVNO PAKIRANJE, odmerek 140 mg (BREZ BLUE-BOXA)
STATEMENT OF ACTIVE SUBSTANCE(S) Each hard capsule contains cabozantinib (S)-malate equivalent to 20 mg of cabozantinib. 
NAVEDBA ENE ALI VEČ ZDRAVILNIH UČINKOVIN Ena trda kapsula vsebuje kabozantinib (S)-malat v količini, ki ustreza 20 mg kabozantiniba.
Eye disorders vision blurred cataract, conjunctivitis 
Očesne bolezni zamegljen vid katarakta, konjunktivitis
20 mg and 80 mg 
trda kapsula 20 mg in 80 mg 100 mg odmerek
PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BLISTER CARD OF 28 DAY PACK, 100 mg dose (WITHOUT BLUE BOX) 
PRETISNA ZGIBANKA 28-DNEVNO PAKIRANJE, odmerek 100 mg (BREZ BLUE-BOXA)
140 mg/day dose 
140 mg/dan, zaloga za 28 dni)
• Joint pain, muscle spasms 
• bolečine v sklepih, mišični spazmi
Name and address of the manufacturer responsible for batch release 
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Wound complications have been observed with cabozantinib. 
Pri uporabi kabozantiniba so opazili zaplete z ranami.
Haemorrhage 
MedDRA
• Facial pain 
• možganska kap
- sudden loss of vision (frequency rare). 
- nenadna izguba vida (pogostnost redka).
- have low blood pressure or uncontrolled high blood pressure. 
- imate nizek krvni tlak ali nekontroliran visok krvni tlak.
However, it is not possible to definitively determine whether these events are related directly to these risk factors, to Tadalafil Lilly, to sexual activity, or to a combination of these or other factors. 
Vendar pa ni mogoče dokončno potrditi, ali so omenjeni dogodki neposredno povezani s temi dejavniki tveganja, z zdravilom Tadalafil Lilly, s spolno aktivnostjo ali s kombinacijo naštetih ali drugih dejavnikov.
If you experience any of the following side effects stop using the medicine and seek medical help immediately: - allergic reactions including rashes (frequency uncommon). 
Če opazite kateregakoli od naslednjih neželenih učinkov, prenehajte uporabljati to zdravilo in nemudoma poiščite zdravniško pomoč: - alergijske reakcije, vključno z izpuščaji (pogostnost neznana).
Antidiabetic medicinal products Specific interaction studies with antidiabetic medicinal products were not conducted. 
Specifične študije medsebojnega delovanja z antidiabetičnimi zdravili niso bile opravljene.
de la Industria 30, Alcobendas, 28108 Madrid, Spain 
de la Industria 30, Alcobendas, 28108 Madrid, Španija
However, you have been given the dose of one 20 mg tablet as your doctor has decided that the recommended dose of 10 mg is too weak. 
Vam je bil predpisan odmerek ene 20 mg tablete, saj je vaš zdravnik presodil, da je priporočeni odmerek 10 mg prešibek.
The patients should be informed not to take Tadalafil Lilly in such combinations. 
Bolnika je treba opozoriti naj ne jemlje zdravila Tadalafil Lilly v takšnih kombinacijah.
Do not take Tadalafil Lilly if you are already taking nitrates. 
Ne vzemite zdravila Tadalafil Lilly, če že jemljete nitrate.
Take Tadalafil Lilly with water every day at approximately the same time, either with or without food. 
Zdravilo Tadalafil Lilly vzemite z vodo vsak dan ob približno istem času, s hrano ali brez nje.
- are taking any form of organic nitrate or nitric oxide donors such as amyl nitrite. 
- jemljete kakršno koli obliko organskega nitrata ali donorje dušikovega oksida, kot je amil nitrit.
Children and adolescents Tadalafil Lilly is not intended for use by children and adolescents under the age of 18. 
Zdravilo Tadalafil Lilly ni namenjeno za uporabo pri otrocih in mladostnikih, mlajših od 18 let.
Tadalafil Lilly may still be effective up to 36 hours after taking the tablet. 
Zdravilo Tadalafil Lilly je lahko učinkovito še do 36 ur po zaužitju tablete.
Tadalafil exposure (AUC) in patients with diabetes was approximately 19 % lower than the AUC value for healthy subjects. 
Izpostavitev tadalafilu (AUC) je bila pri bolnikih s sladkorno boleznijo približno 19 % nižja kot vrednost AUC za zdrave osebe.
- priapism, a prolonged and possibly painful erection after taking Tadalafil Lilly (frequency rare). 
- priapizem, podaljšana in morda boleča erekcija po jemanju zdravila Tadalafil Lilly (pogostnost redka).
Start with the pill from the blister pack that corresponds with the day you start taking Tadalafil Lilly. 
Začnite s tableto iz pretisnega omota, ki ustreza dnevu, ko začnete jemati zdravilo Tadalafil Lilly.
Although other risk factors were present in some cases (such as age, diabetes, hypertension and previous hearing loss history) patients should be advised to stop taking tadalafil and seek prompt medical attention in the event of sudden decrease or loss of hearing. 
Čeprav so bili v določenih primerih prisotni drugi dejavniki tveganja (npr. starost, sladkorna bolezen, hipertenzija in predhodna izguba sluha v anamnezi), je treba bolnikom svetovati, naj v primeru nenadnega poslabšanja ali izgube sluha prenehajo jemati tadalafil in poiščejo takojšnjo zdravniško pomoč.
The maintenance of the effect was evaluated in an open-label extension to one of the studies, which showed that the improvement in total international prostate symptom score seen at 12 weeks was maintained for up to 1 additional year of treatment with Tadalafil Lilly 5 mg. 
Vzdrževanje učinka je bilo ocenjeno v odprti nadaljevalni fazi ene od študij, ki je pokazala, da je bilo izboljšanje skupnega rezultata na mednarodni lestvici prostatičnih simptomov, ki je bilo ugotovljeno pri 12 tednih, ohranjeno do 1 dodatnega leta zdravljenja z zdravilom Tadalafil Lilly 5 mg.
If you have taken or are planning to take Tadalafil Lilly, avoid excessive drinking (blood alcohol level of 0.08% or greater), since this may increase the risk of dizziness when standing up. 
Če ste vzeli ali nameravate vzeti zdravilo Tadalafil Lilly, se izogibajte čezmernemu pitju (raven alkohola v krvi 0,08 % ali več), ker lahko to poveča tveganje za omotico ob vstajanju.
You may take a Tadalafil Lilly tablet at least 30 minutes before sexual activity. 
Tableto zdravila Tadalafil Lilly lahko zaužijete najmanj 30 minut pred spolno aktivnostjo.
The overall safety results from this study were generally consistent with the known safety profile of tadalafil and with adverse events (AEs) expected in a paediatric DMD population receiving corticosteroids. 
Skupni rezltati o varnosti so bili v tej študiji na splošno skladni z znanim varnostnim profilom tadalafila in z neželenimi učinki, pričakovanimi v pediatrični populaciji z DMD, ki prejema kortikosteroide.
Once a day dosing of Tadalafil Lilly may be useful to men who anticipate having sexual activity two or more times per week. 
Odmerjanje enkrat na dan je lahko koristno za moške, ki pričakujejo spolno aktivnost dvakrat ali večkrat na teden.
Tadalafil Lilly was studied in 4 clinical studies of 12 weeks duration enrolling over 1500 patients with signs and symptoms of benign prostatic hyperplasia. 
Zdravilo Tadalafil Lilly je bilo proučevano v 4 kliničnih študijah, ki so trajale 12 tednov in so vključevale prek 1500 bolnikov z znaki in simptomi benigne hiperplazije prostate.
With regard to those interaction studies where only the 10 mg tadalafil dose was used, clinically relevant interactions at higher doses cannot be completely ruled out. 
Glede na te študije medsebojnega delovanja, pri katerih je bil uporabljan samo odmerek 10 mg tadalafila, klinično pomembnih medsebojnih delovanj pri višjih odmerkih ni mogoče popolnoma izključiti.
Since benign prostatic hyperplasia and prostate cancer may have the same symptoms, your doctor will check you for prostate cancer before starting treatment with Tadalafil Lilly for benign prostatic hyperplasia. 
Ker imata benigna hiperplazija prostate in rak prostate lahko enake simptome, vas bo vaš zdravnik pred začetkom zdravljenja vaše benigne hiperplazije prostate z zdravilom Tadalafil Lilly pregledal za rak prostate.
Some men taking Tadalafil Lilly in clinical studies have reported dizziness. 
Nekateri moški, ki so zdravilo Tadalafil Lilly jemali v kliničnih študijah, so poročali o omotici.
Tadalafil Lilly and other treatments for erectile dysfunction The safety and efficacy of combinations of Tadalafil Lilly and other PDE5 inhibitors or other treatments for erectile dysfunction have not been studied. 
Zdravilo Tadalafil Lilly in druga zdravljenja erektilne disfunkcije Varnosti in učinkovitosti kombinacij zdravila Tadalafil Lilly in drugih zaviralcev PDE5 ali drugih zdravljenj za erektilno disfunkcijo niso preučevali.
If you experience sudden decrease or loss of vision, stop taking Tadalafil Lilly and contact your doctor immediately. 
Če doživite nenadno poslabšanje ali izgubo vida, prenehajte jemati zdravilo Tadalafil Lilly in se takoj obrnite na svojega zdravnika.
As this may be relevant for all patients exposed to tadalafil, the patient should be advised that in case of sudden visual defect, he should stop taking Tadalafil Lilly and consult a physician immediately (see section 4.3). 
Ker je to morda pomembno za vse bolnike, ki so izpostavljeni tadalafilu, je treba bolnika opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo Tadalafil Lilly in o tem nemudoma obvesti svojega zdravnika (glejte poglavje 4.3).
Although the frequency of reports of dizziness in placebo and tadalafil arms in clinical trials was similar, patients should be aware of how they react to Tadalafil Lilly, before driving or using machines. 
Kljub temu, da so bile pogostnosti poročanja o omotici v skupinah prejemanja placeba in tadalafila v kliničnih preskušanjih podobne, naj se bolniki pred vožnjo ali uporabo strojev zavedajo, kako se odzovejo na zdravilo Tadalafil Lilly.
- chest pain - do not use nitrates but seek immediate medical assistance (frequency uncommon). 
- bolečina v prsnem košu - ne uporabljajte nitratov, ampak nemudoma poiščite zdravniško pomoč
Following sexual stimulation Tadalafil Lilly works by helping the blood vessels in your penis to relax, allowing the flow of blood into your penis. 
Po spolni stimulaciji zdravilo Tadalafil Lilly deluje tako, da pomaga pri sproščanju krvnih žil v vašem penisu in s tem omogoča dotok krvi v penis.
What Tadalafil Lilly is and what it is used for What you need to know before you take Tadalafil Lilly How to take Tadalafil Lilly 
Kaj je zdravilo Tadalafil Lilly in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Tadalafil Lilly Kako jemati zdravilo Tadalafil Lilly
Tadalafil is a selective, reversible inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5). 
Mehanizem delovanja Tadalafil je selektivni reverzibilni zaviralec ciklični gvanozin-monofosfat (cGMP)-specifične fosfodiesteraze tipa 5 (PDE5).
Tadalafil Lilly has been shown to improve these urinary symptoms as early as 1-2 weeks after starting treatment. 
Za zdravilo Tadalafil Lilly je dokazano, da te simptome sečil izboljša že v 1-2 tednih po začetku zdravljenja.
Tadalafil Lilly, should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anaemia, multiple myeloma or leukaemia). 
Zdravilo Tadalafil Lilly je potrebno previdno uporabljati pri bolnikih z anatomsko deformacijo penisa (kot so ukrivljenost, kavernozna fibroza ali Peyroniejeva bolezen), ali pri bolnikih s stanji, ki bi lahko povečala dovzetnost za priapizem (kot so srpastocelična anemija, multipli mielom ali levkemija).
Also, patients with erectile dysfunction in all severity categories reported improved erections whilst taking Tadalafil Lilly (86 %, 83 %, and 72 % for mild, moderate, and severe, respectively, as compared to 45 %, 42 %, and 19 % with placebo). 
Nadalje so bolniki z erektilnimi disfunkcijami v vseh kategorijah resnosti poročali o izboljšanih erekcijah v času jemanja zdravila Tadalafil Lilly (86 %, 83 % oziroma 72 % za blago, zmerno oziroma hudo v primerjavi s 45 %, 42 % oziroma 19 % pri placebu).
PDE5 inhibitors, such as Tadalafil Lilly, have been shown to increase the hypotensive effects of this medicine. 
Zaviralci PDE5, kot je Tadalafil Lilly, dokazano povečujejo hipotenzivne učinke tega zdravila.
It is not known if Tadalafil Lilly is effective in patients who have had: - pelvic surgery. 
Ni znano, če je zdravilo Tadalafil Lilly učinkovito pri bolnikih, ki so imeli: - operacijo v medenici.
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 22. 
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJA ZA PROMET Datum prve odobritve: 22. marec 2017
However, as a formal drug-drug interaction study evaluating the effects of tadalafil and 5-alpha reductase inhibitors (5-ARIs) has not been performed, caution should be exercised when tadalafil is coadministered with 5-ARIs. 
Ker pa uradna študija medsebojnega delovanja zdravil, ki bi ocenila učinke tadalafila in zaviralcev 5-alfa reduktaze (5-ARI), ni bila opravljena, je potrebna previdnost ob sočasni uporabi tadalafila s 5-ARI.
Tadalafil Lilly does not treat prostate cancer. 
Zdravilo Tadalafil Lilly ne zdravi raka prostate.
The majority of headaches reported with Tadalafil Lilly once-a-day dosing are experienced within the first 10 to 30 days of starting treatment. 
Večino glavobolov, o katerih poročajo bolniki, ki jemljejo zdravilo Tadalafil Lilly v odmerku enkrat na dan, bolniki občutijo v prvih 10 do 30 dneh po začetku zdravljenja.
In dogs given tadalafil daily for 6 to 12 months at doses of 25 mg/kg/day (resulting in at least a 3-fold greater exposure [range 3.7 - 18.6] than seen in humans given a single 20 mg dose) and above, there was regression of the seminiferous tubular epithelium that resulted in a decrease in spermatogenesis in some dogs. 
Pri psih, ki so tadalafil prejemali dnevno 6 do 12 mesecev v odmerkih 25 mg/kg/dan (kar pomeni vsaj 3-krat večjo izpostavitev [razpon 3,718,6], kot je bila opažena pri ljudeh pri enkratnem odmerku 20 mg) in več, je prišlo do regresije epitela semenskih cevk, kar je pri nekaterih psih povzročilo zmanjšanje spermatogeneze.
Tadalafil Lilly will not help you if you do not have erectile dysfunction. 
Zdravilo Tadalafil Lilly vam ne bo pomagalo, če nimate erektilne disfunkcije.
The improvement in the total international prostate symptom score with Tadalafil Lilly 5 mg in the four studies were -4.8, -5.6, -6.1 and -6.3 compared to -2.2, -3.6, -3.8 and -4.2 with placebo. 
Izboljšanje skupnega rezultata na mednarodni lestvici prostatičnih simptomov z zdravilom Tadalafil Lilly 5 mg v štirih študijah je znašalo -4,8, -5,6, -6,1 in -6,3 v primerjavi z -2,2, -3,6, -3,8 in -4,2 s placebom.
The improvements in total international prostate symptom score occurred as early as 1 week. 
Izboljšanja skupnega rezultata na mednarodni lestvici prostatičnih simptomov so se pokazala že po 1